CHICAGO (EGMN) - Despite delaying progression of incurable squamous cell carcinoma of the head and neck after failure of standard platinum-based therapy, the novel agent zalutumumab failed to meet the primary end point for prolonging overall survival in a randomized, phase III trial."Although a trend for zalutumumab was observed, zalutumumab did not significantly improve overall survival," said Dr. Jean-Pascal H. Machiels, principal investigator of the ZALUTE (Zalutumumab in Patients With Noncurable...